Envista Holdings Corp. manufactures and markets dental products for diagnosing, treating and preventing dental conditions. The firm operates through the following segments; Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. The Equipment & Consumables segments develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products. It offers dental consumables, equipment, and services to dental professionals. The company was founded on August 29, 2018 and is headquartered in Brea, CA.
NVST Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for NVST, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Envista Holdings Corp ranked in the 53th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 64.67% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for NVST, they are:
Its compound free cash flow growth rate, as measured over the past 0.47 years, is -0.04% -- higher than only 22.59% of stocks in our DCF forecasting set.
Envista Holdings Corp's weighted average cost of capital (WACC) is 6%; for context, that number is higher than only 7.3% of tickers in our DCF set.
The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than only 0% of stocks in its sector (Healthcare).
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
DVA, LH, SNY, DGX, and FONR can be thought of as valuation peers to NVST, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.